Pharma BD Deal Intelligence
Roche paid $2.7B upfront for Carmot Therapeutics to enter the GLP-1 obesity race with three clinical-stage candidates—including oral formulations that could differentiate against Novo and Lilly's injectable dominance. A late-mover bet that the obesity market sustains multiple winners.
Roche acquired Carmot Therapeutics for $2.7B for anti-obesity drug development.
Roche to acquire obesity-focused Carmot Therapeutics for $2.7 billion, entering the intensely competitive obesity drug market with three clinical-stage…
Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388: placebo-adjusted weight loss of 22.5% (p<0.001) at 48 weeks (24 mg);…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Roche acquired Carmot Therapeutics in an all-cash deal of $2.7 billion upfront (plus up to $400 million in milestone payments, ~$3.1 billion total), announced December 4, 2023 and completed January 29, 2024, to enter the GLP-1 obesity/cardiometabolic market. The deal brought Roche three clinical-stage incretin assets: CT-388 (an injectable dual GLP-1/GIP receptor agonist), CT-996 (an oral small-molecule GLP-1 receptor agonist) and CT-868 (a dual GLP-1/GIP agonist for type 1 diabetes). Lead asset CT-388 has since validated the thesis: on January 27, 2026 Roche reported positive Phase 2 topline data (trial CT388-103) showing 22.5% placebo-adjusted weight loss at 48 weeks at the 24 mg dose (p<0.001), with no weight-loss plateau observed — efficacy in the same range as Eli Lilly's tirzepatide. Roche said the Phase 3 program (Enith1 and Enith2) would begin in Q1 2026, and is also developing CT-388 as a combination asset with the Zealand-partnered amylin analog petrelintide. CT-996 remains in development (Roche licensed related IP from Structure Therapeutics for $100M in January 2026), positioning Roche as a credible late-mover across injectable and oral obesity.
100M US cases/yr · $100.0B 2030 obesity market projected
CT-388 GLP-1/GIP agonist showed 22.5% weight loss; CT-996 oral GLP-1; Phase 3 planned 2026
GLP-1/GIP dual agonists lead the obesity market (Mounjaro, Zepbound). Oral formulations are a critical next frontier. CT-388 and CT-996 from Carmot represent emerging competition. The market is estimated at over $100B by 2030, with access and supply chain as primary constraints.
4M US cases/yr · $50.0B Global Obesity Therapeutics (2025E)
Obesity affects over 40% of US adults. GLP-1 receptor agonists have revolutionized treatment. Roche acquired Carmot's three clinical GLP-1/GIP candidates including injectable (CT-388, CT-868) and oral (CT-996) to enter this massive market.
Dominated by Novo Nordisk (Wegovy) and Eli Lilly (Zepbound). Roche trails by 2-3 years. CT-388 18.8% weight loss at 24wk is competitive but below tirzepatide benchmarks. Oral CT-996 could differentiate.
Roche completed $2.7B acquisition of Carmot Therapeutics, gaining GLP-1/GIP agonist pipeline for obesity and diabetes markets.
Roche completed $3.1B acquisition of Carmot Therapeutics ($2.7B upfront + $400M milestones), gaining three clinical-stage GLP-1/GIP agonists for obesity.
Roche progressed CT-388 (injectable GLP-1/GIP) and CT-996 (oral GLP-1) through development, competing in the rapidly growing obesity market.
Roche reported positive Phase 2 topline data for lead Carmot asset CT-388 (dual GLP-1/GIP agonist, trial CT388-103): 22.5% placebo-adjusted weight loss at 48 weeks (24 mg dose, p<0.001), no plateau. Phase 3 program (Enith1/Enith2) expected to start Q1 2026; CT-388 also advancing as a combination asset with petrelintide.
Gives Roche a credible obesity pipeline in a multi-hundred-billion-dollar market. CT-996 (oral) could differentiate vs Lilly/Novo injectables. Data in 2025-2026 pivotal.
Carmot gives Roche competitive obesity entry. Oral and injectable candidates in development. Outcome depends on Phase 3 data vs Lilly/Novo Nordisk.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Carmot Therapeutics Inc. (this deal) | 2023 | $2.7B | 72 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2023 deals · Roche Holding AG deals · Metabolic deals